AzurRx BioPharma, Inc.
AZRX · NASDAQ
12/31/2024 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $904 | $5,888 | $8,681 | $4,986 |
| G&A Expenses | $14,717 | $7,295 | $6,063 | $8,236 |
| SG&A Expenses | $14,717 | $7,295 | $6,063 | $8,236 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $20,545 | $0 | $210 |
| Operating Expenses | $15,621 | $26,433 | $14,744 | $13,432 |
| Operating Income | -$15,621 | -$26,433 | -$14,744 | -$13,432 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$2,438 | -$6,239 | -$434 | -$102 |
| Pre-Tax Income | -$18,059 | -$32,671 | -$15,178 | -$13,534 |
| Tax Expense | $0 | -$398 | $0 | $0 |
| Net Income | -$18,059 | -$32,671 | -$15,178 | -$13,534 |
| % Margin | – | – | – | – |
| EPS | -5.33 | -5.903 | -6.77 | -8.77 |
| % Growth | 9.7% | 12.8% | 22.8% | – |
| EPS Diluted | -5.33 | -5.903 | -6.77 | -8.77 |
| Weighted Avg Shares Out | 3,435 | 5,535 | 2,243 | 1,544 |
| Weighted Avg Shares Out Dil | 3,435 | 5,535 | 2,243 | 1,544 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $5,841 | $434 | $102 |
| Depreciation & Amortization | $0 | $38 | $1,020 | $798 |
| EBITDA | -$15,621 | -$26,831 | -$13,724 | -$12,633 |
| % Margin | – | – | – | – |